FDA Approves First Blood Test for Alzheimer’s Diagnosis Starting at Age 40
How 2 Israeli newsrooms covered this story — translated into English and compared side by side.
First reported by Behadrei Haredim · 18 hours ago
What happened
The FDA has approved PrecivityAD2, the first blood test for Alzheimer’s diagnosis in adults aged 40 and above with cognitive symptoms. Developed by C2N Diagnostics, the test detects amyloid plaques with high accuracy and offers a less invasive alternative to current methods. This approval enables earlier diagnosis and treatment, with availability expected in the U.S. later this year.
- 01FDA approves PrecivityAD2 blood test for Alzheimer’s diagnosis starting at age 40.
- 02Test detects amyloid plaques with over 97% accuracy in symptomatic adults.
- 03Developed by C2N Diagnostics using advanced mass spectrometry technology.
- 04Test complements medical evaluation, not intended for asymptomatic screening.
- 05Early diagnosis aids timely treatment with new disease-modifying therapies.
- 06FDA approval may increase insurance coverage and accessibility in the U.S.
Summary translated & synthesized from the sources below by baba. Read each original for the full report.
Full coverage · 2 outlets
The same event, reported separately by each newsroom. Open a few to compare what each emphasizes — and what they leave out.
